News Medical

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the ...
Nasdaq

Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered ...
News Medical

Exalenz Bioscience initiates BreathID clinical study to detect primary liver cancer

Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the ...
Fierce Healthcare

Exalenz Bioscience Adds The George Washington University Department of Emergency Medicine to Its Expanding Roster of U.S.

BreathID ® Breath Test System for H. pylori Detection Will Advance Care of Patients with Abdominal Pain “The BreathID system fits perfectly with our goal of improving bedside diagnostic testing in the ...
Business Wire

Exalenz Bioscience Adds The George Washington University Department of Emergency Medicine to Its Expanding Roster of U.S. Customers

WILMINGTON, Del.--(BUSINESS WIRE)--Exalenz Bioscience, Inc., a provider of breath testing equipment for the diagnosis and management of digestive system and liver conditions, today announced the ...